Non-Alcoholic Steatohepatitis (NASH): Current and Future Trends
Sponsored by: GlobalData
Date: 16 October
Days to go: 0
Time: 4PM London/11AM New York
Expert Presentation Overview
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). Patients with NASH display liver inflammation with hepatocyte injury in the form of ballooning, with or without fibrosis, in addition to the presence of a fatty liver. NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer. As the most common form of chronic liver disease in developed countries, the prevalence of NAFLD in the US ranges from 20% to 46%, and the prevalence of NASH spans from 2% to 12%.
Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch. This report is an update to GlobalData’s 2017 publication, ‘OpportunityAnalyzer: NASH – Opportunity Analysis and Forecasts to 2026’, and attempts to address this uncertainty and provide insight on what to expect from the NASH market to 2026, supported by GlobalData’s extensive primary and secondary research.
In this expert presentation Dr. Thomas Moore, a Healthcare Analyst at GlobalData, will present the changing NASH treatment landscape between 2016 and 2026, drawing on insights from GlobalData’s report, ‘Non-Alcoholic Steatohepatitis: Dynamic Market Forecast to 2026’. The current treatment options and drug pipeline for NASH will be covered, including a discussion on GlobalData’s sales forecast for the NASH market. The webinar will include insights from KOLs covering the challenges expected to be faced by companies looking to enter the NASH market, as well as the opportunities which are likely to remain by the end of the forecast period. Dr. Christopher Pace, a Therapy Area Director at GlobalData, will moderate a Q&A session following the presentation.
Senior Healthcare Analyst
Thomas Moore, PhD is a Senior Healthcare Analyst at GlobalData in London. Since joining GlobalData in 2016, Thomas has worked across several therapy areas, providing market commentary and analysis through both primary and secondary research, and extensive disease market forecasting. Thomas’ areas of expertise include infectious diseases and ophthalmology, having published reports and briefs covering C. difficile infections, Glaucoma, HIV, and travel vaccines. He received his PhD from the University of Sussex, where he also carried out his undergraduate MChem studies. Thomas’s doctoral research focused on the development of inhibitors of protein-protein interactions, and he worked both as a synthetic organic chemist, and as a computational chemist, modelling drug-protein interactions. As a doctoral student at the University of Sussex, Thomas spent one term as the elected student representative on university council, and also tutored high-school and college level science, including the running of weekly medicinal chemistry training sessions for doctoral students.
Christopher J. Pace,
Therapy Area Director
Christopher J. Pace, PhD, is a Therapy Area Director at GlobalData in Boston, where he primarily oversees the infectious diseases portfolio of syndicated market research reports. Since joining GlobalData in 2013, Dr. Pace has extensively researched and provided in-depth analysis and commentary on a wide range of topics within the infectious diseases space and across the pharmaceutical and healthcare industries, with areas of expertise including hepatitis C and HIV therapeutics, vaccine R&D and immunization policy, and antibiotics. Dr. Pace holds a PhD in Chemistry from Boston College and a BS in Chemistry from Fairfield University. Dr. Pace’s doctoral research focused on the use of unnatural amino acids as tools for examining the fundamental energetics of aromatic interactions in proteins. While at Boston College, Christopher tutored college-level chemistry and biochemistry in the greater Boston area, and he also served as the Boston College Campus Representative for the Northeastern Section Younger Chemists Committee (NSYCC).
Key Learning Objectives
- Learn how GlobalData expects the NASH market landscape to change between 2016 and 2026 across the 7 major markets (US, France, Germany, Italy, Spain, the UK and Japan)
- Gain insight on the late-stage pipeline for NASH, including which products GlobalData expects to succeed, and why.
- Learn how KOLs and Payers interviewed by GlobalData foresee the NASH market will develop and the extent which currently unmet needs are met by the NASH pipeline.
- Identify which companies are set to be the major players in NASH during the forecast.
- Managers/Senior Managers
- Associate Directors/Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers
- Market Access
- Health Economics and Outcomes Research
- Pharmaceutical Pricing
- Pharmaceutical Licensing
- Government and Public Affairs
- Drug Development
- Regulatory Affairs
- Medical Affairs
- Market Access Consultant